In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk

Research output: Contribution to journalComment/debatepeer-review

Abstract

SOURCE CITATION: Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478-1490. 36877098.

Original languageEnglish (US)
Pages (from-to)JC69
JournalAnnals of internal medicine
Volume176
Issue number6
DOIs
StatePublished - Jun 1 2023

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk'. Together they form a unique fingerprint.

Cite this